Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions (2016 - 2026)

Amphastar Pharmaceuticals has reported Tax Provisions over the past 13 years, most recently at -$21.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 453.02% year-over-year to -$21.2 million; the TTM value through Dec 2025 reached -$3.1 million, down 110.55%, while the annual FY2025 figure was -$3.1 million, 110.55% down from the prior year.
  • Tax Provisions for Q4 2025 was -$21.2 million at Amphastar Pharmaceuticals, down from $4.2 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $14.0 million in Q3 2023 and troughed at -$21.2 million in Q4 2025.
  • A 5-year average of $4.9 million and a median of $5.8 million in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: surged 7560.0% in 2021 and later plummeted 453.02% in 2025.
  • Year by year, Tax Provisions stood at $3.5 million in 2021, then skyrocketed by 107.69% to $7.3 million in 2022, then tumbled by 35.9% to $4.7 million in 2023, then rose by 28.35% to $6.0 million in 2024, then plummeted by 453.02% to -$21.2 million in 2025.
  • Business Quant data shows Tax Provisions for AMPH at -$21.2 million in Q4 2025, $4.2 million in Q3 2025, and $8.3 million in Q2 2025.